These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16909049)

  • 1. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 6. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulating the cell's appetite for itself.
    Simonsen A; Stenmark H
    Nat Chem Biol; 2007 Jun; 3(6):304-6. PubMed ID: 17510644
    [No Abstract]   [Full Text] [Related]  

  • 8. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 9. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

  • 10. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V; Herrling P
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroprotection in progressive brain disorders.
    Djaldetti R; Lev N; Melamed E
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.
    Exp Biol Med (Maywood); 2008 Nov; 233(11):vi. PubMed ID: 18957631
    [No Abstract]   [Full Text] [Related]  

  • 14. New therapeutic strategies for treatment of neurodegenerative diseases.
    Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3917-8. PubMed ID: 20044916
    [No Abstract]   [Full Text] [Related]  

  • 15. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V; Herrling P
    Neurodegener Dis; 2011; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract]   [Full Text] [Related]  

  • 16. List of drugs in development for neurodegenerative diseases: update October 2011.
    Pogačić Kramp V
    Neurodegener Dis; 2012; 9(4):210-83. PubMed ID: 22222285
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic potential of thyreoliberin (TRH) and its analogues as antiepileptic and neuroprotective drugs].
    Jantas D
    Przegl Lek; 2010; 67(11):1179-85. PubMed ID: 21442973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 19. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
    ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.